COMP <GO>
APYX vs LLY // ENTERPRISE SCALE & MARKET CAP
Apyx Medical Corporation (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: APYX 0
— LLY 11
▲ ENTERPRISE SCALE & MARKET CAP LEADER: LLY
LAST: $2.60 (-3.35%) • MKT CAP: $113.3M
market-cap
$113.3M
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.29T
market-cap
$1.29T
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (APYX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | APYX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.50% | 83.64% | -21.14 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.90% | 32.36% | -61.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.04% | 2.30% | -10.34 | LLY | /fcf-yield <GO> |
| Operating Margin | -12.20% | 40.21% | -52.41 | LLY | /operating-margins <GO> |
| Net Profit Margin | -21.20% | 31.90% | -53.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 9.90% | 45.51% | -35.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.75 | 9.29 | -8.54 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.1 | 66.6 | -17.45 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $113.3M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | APYX REV | LLY REV | APYX GROSS % | LLY GROSS % | APYX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $52.8M | $65.18B | 62.5% | 83.0% | -$9.1M | $16.81B |
| FY 2024 | $48.1M | $45.04B | 61.0% | 81.3% | -$18.8M | $8.82B |
| FY 2023 | $52.3M | $34.12B | — | 79.3% | -$5.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
APYX // BETA —
LLY // BETA 0.51